NMN/NR (Nicotinamide Mononucleotide/Riboside) Cost in Arizona 2026

What NMN and NR Actually Cost in Arizona Right Now

Arizona residents can expect to spend between $40 and $150 per month on NAD+ precursor supplements or compounded formulations, with the exact price depending on whether they choose over-the-counter NR, retail NMN, or prescription compounded NMN from a 503A pharmacy.

NR (nicotinamide riboside) remains the more accessible and affordable option. Tru Niagen, the most widely studied commercial NR product, retails for approximately $40 to $50 per month at a 300 mg daily dose through Arizona pharmacies, grocery chains, and online retailers [1]. Elysium Health's Basis (which pairs NR with pterostilbene) runs $50 to $60 per month at retail. These products are classified as dietary supplements and do not require a prescription.

NMN pricing is more variable. The FDA's 2022 determination that NMN could not be marketed as a conventional dietary supplement (because of its prior investigation as a new drug candidate by Metro International Biotech) shifted much of the NMN market toward compounding pharmacies and direct-to-consumer channels operating in regulatory gray areas [2]. Arizona-based consumers purchasing NMN capsules from online supplement retailers typically pay $50 to $100 per month for doses ranging from 250 mg to 1 to 000 mg daily. Compounded NMN from a licensed 503A pharmacy in Arizona, which requires a prescriber's order, generally costs $80 to $150 per month depending on the formulation (oral capsule, sublingual tablet, or nasal spray) and the target dose [3].

Price variation is significant. A 30-day supply of 500 mg NMN capsules can range from $35 at high-volume online retailers to $120 at boutique longevity clinics in Scottsdale or Phoenix. That spread reflects differences in third-party testing, purity verification, and bioavailability claims rather than differences in the active molecule itself.

Why Insurance Does Not Cover NMN or NR in Arizona

No commercial health plan, Medicare Part D formulary, or Arizona Health Care Cost Containment System (AHCCCS, Arizona's Medicaid program) covers NMN or NR in any formulation. The reason is straightforward: coverage requires FDA approval for a specific therapeutic indication, and neither compound has one.

NR is regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Supplements sit outside the pharmacy benefit entirely. NMN occupies a more complicated regulatory space. After the FDA's November 2022 decision to exclude NMN from the dietary supplement category, the compound has no clear consumer product classification [2]. It is not an approved drug and (per the FDA's position) not a lawful supplement. Compounded NMN prepared by a 503A pharmacy under a patient-specific prescription sidesteps this classification issue, but compounded preparations are excluded from formulary coverage by virtually every payer.

AHCCCS specifically limits its formulary to FDA-approved prescription drugs and selected over-the-counter medications with established therapeutic classifications [4]. An AHCCCS spokesperson noted in 2024 that "products without an FDA-approved NDA or ANDA are not eligible for Medicaid drug rebate agreements and therefore cannot appear on the preferred drug list." This policy applies uniformly to NMN, NR, and other NAD+ precursors.

The Endocrine Society's 2024 scientific statement on NAD+ metabolism acknowledged preclinical promise but stated that "evidence from adequately powered, long-duration randomized controlled trials in humans is insufficient to support clinical recommendations for NAD+ precursor supplementation" [5]. Without guideline endorsement, even employer-sponsored plans with wellness spending accounts rarely reimburse these products.

The Evidence Behind NMN and NR Pricing Claims

Arizona consumers evaluating whether $40 to $150 per month represents reasonable value should understand what the clinical data actually shows. The evidence base is growing but remains early-stage.

Yoshino et al. published the first major randomized controlled trial of NMN in humans in Science in 2021. That study enrolled 25 postmenopausal women with prediabetes and showed that 250 mg/day oral NMN for 10 weeks improved skeletal muscle insulin sensitivity by approximately 25% compared to placebo, as measured by hyperinsulinemic-euglycemic clamp [6]. The trial was small. It did not measure patient-reported outcomes, longevity endpoints, or NAD+ levels in tissues other than muscle and blood.

For NR, the evidence is somewhat broader. A 2018 randomized trial by Martens et al. (N=24 lean, healthy older adults) found that 1 to 000 mg/day NR for 6 weeks raised whole-blood NAD+ levels by approximately 60% and reduced systolic blood pressure by 5 mmHg in participants with Stage 1 hypertension [7]. Dollerup et al. conducted a larger trial (N=40 obese men) published in the American Journal of Clinical Nutrition in 2020, showing that 2 to 000 mg/day NR for 12 weeks increased NAD+ metabolites in skeletal muscle but did not improve insulin sensitivity, mitochondrial function, or body composition [8].

Dr. Charles Brenner, the biochemist who discovered NR's role as a vitamin and NAD+ precursor, has stated: "Raising NAD is real and reproducible in human trials, but we have not yet identified the clinical populations and dosing regimens that translate elevated NAD into measurable health outcomes" [9]. That honest assessment should inform purchasing decisions. Arizona consumers are paying for a biochemical effect (increased circulating NAD+) whose clinical downstream benefits remain unproven in rigorous trials.

How Arizona 503A Compounding Pharmacies Fit In

Compounded NMN is legally available in Arizona through pharmacies holding a valid 503A license from the Arizona State Board of Pharmacy. This pathway exists because 503A pharmacies may compound any non-commercially-available drug product when they receive a valid patient-specific prescription from a licensed prescriber.

Arizona follows the federal framework established by the Drug Quality and Security Act (DQSA) of 2013 [10]. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare NMN capsules, sublingual tablets, or other dosage forms for an individual patient if three conditions are met: the prescriber has an established patient relationship, the compound is not a copy of a commercially available FDA-approved product (NMN has none, so this is satisfied automatically), and the pharmacy does not compound in anticipation of receiving prescriptions beyond limited quantities.

Several Arizona-based 503A pharmacies in the Phoenix and Tucson metropolitan areas currently offer compounded NMN. Typical formulations include 250 mg and 500 mg oral capsules and 100 mg to 250 mg sublingual troches. Pricing runs $80 to $150 per month, with sublingual and higher-dose formulations at the upper end. Some compounding pharmacies also offer combination formulations pairing NMN with trimethylglycine (TMG), resveratrol, or other compounds marketed as NAD+ support.

Quality varies. Arizona consumers should verify that their compounding pharmacy holds current accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or has passed a recent Arizona Board of Pharmacy inspection without deficiencies. Ask the pharmacy whether it conducts third-party potency and sterility testing on finished NMN products. Not all do.

Telehealth Access to NMN in Arizona

Arizona law permits prescribers to order compounded NMN via telehealth without requiring an initial in-person visit. This is a direct result of Arizona's telehealth parity legislation (A.R.S. 36-3602), which broadly authorizes the practice of medicine through audio, video, or asynchronous store-and-forward technologies [11].

A telehealth consultation for NAD+ precursor therapy in Arizona typically costs $75 to $200 for the initial visit and $50 to $100 for follow-ups. Several national longevity medicine platforms now serve Arizona residents and can transmit prescriptions directly to in-state 503A pharmacies. The total first-month cost (consultation plus compounded product) ranges from $155 to $350. Subsequent months drop to $80 to $250 depending on the formulation, dose, and follow-up schedule.

Some telehealth platforms bundle the consultation fee into the product price. Others charge separately. Ask before enrolling. The bundled pricing model sometimes appears cheaper upfront but may include automatic subscription renewals at higher rates after an introductory period.

Arizona does require that the prescribing clinician hold an active Arizona medical license or a license in a state with which Arizona has an interstate compact agreement. The prescriber must also document a clinical rationale for the NMN order, typically citing the patient's interest in NAD+ optimization as part of a broader age-management or metabolic health protocol.

Strategies to Reduce NMN/NR Costs in Arizona

Out-of-pocket spending on NAD+ precursors adds up quickly. At $100 per month, the annual cost reaches $1,200. Several strategies can reduce that figure meaningfully.

Choose NR over NMN if the goal is simply raising NAD+ levels. Both compounds increase circulating NAD+ in human trials. NR is less expensive, more widely available, and has a clearer regulatory pathway as a dietary supplement. A 2023 head-to-head pharmacokinetic study by Pencina et al. (published in the Journal of Clinical Endocrinology and Metabolism, N=36 healthy adults) found that both 1 to 000 mg NR and 900 mg NMN raised whole-blood NAD+ by 2- to 3-fold at 2 weeks, with no statistically significant difference between the two compounds [12]. If equivalent NAD+ elevation is the objective, NR at $40 to $50 per month represents a 50% to 65% savings over compounded NMN.

Buy in 90-day quantities. Most compounding pharmacies and supplement retailers offer 10% to 20% discounts on 90-day supplies. On a $120/month NMN product, a 15% bulk discount saves $216 annually.

Use a Health Savings Account (HSA) or Flexible Spending Account (FSA). The IRS permits HSA/FSA reimbursement for items prescribed by a physician to treat or prevent a specific medical condition. If a licensed clinician prescribes compounded NMN for a documented condition (such as metabolic syndrome or age-related NAD+ decline as part of a treatment plan), the expense may qualify. Consult a tax professional, as the IRS has not issued specific guidance on NAD+ precursors and enforcement varies.

Compare pharmacy pricing directly. Arizona has no price transparency mandate for compounded medications, so prices vary by 40% to 80% across pharmacies for identical NMN formulations. Call at least three 503A pharmacies before committing.

Skip the "liposomal" and "pharmaceutical-grade" upcharges unless the pharmacy provides a certificate of analysis. Marketing language adds cost. A certificate of analysis (COA) from an independent lab confirming potency and purity is the only quality indicator that matters.

What Arizona Consumers Should Know About NMN Regulation Going Forward

The regulatory status of NMN remains in flux. In March 2023, a group of NMN supplement companies filed a citizen petition asking the FDA to reverse its exclusion of NMN from the dietary supplement category [2]. As of May 2026, the FDA has not issued a final response. The Natural Products Association and several members of Congress have also pushed for legislative fixes that would protect NMN's supplement status.

If the FDA reverses course, NMN prices in Arizona could fall significantly as larger supplement manufacturers re-enter the market with mass-produced formulations. The compounding pharmacy pathway would remain available but might become less attractive on a cost basis. If the FDA maintains its current position, the 503A compounding route will continue as the primary legal access channel for Arizona residents who prefer NMN specifically over NR.

Arizona's own regulatory environment is permissive relative to other states. The Arizona State Board of Pharmacy has not issued any restrictions specific to NMN compounding, and the state's broad telehealth statutes ensure access even in rural counties far from the Phoenix and Tucson compounding pharmacy clusters [11]. Residents in Flagstaff, Yuma, or Sierra Vista can obtain compounded NMN shipped from a licensed Arizona 503A pharmacy via standard courier delivery.

One practical note: the FDA has sent warning letters to several companies marketing NMN with disease claims (e.g., "reverses aging," "treats diabetes") [13]. Arizona consumers should be wary of any vendor, whether online or local, making therapeutic claims about NMN or NR that go beyond what the clinical trial data supports. A product marketed as a cure is a product inviting regulatory action and potential supply disruption.